Dr. Reddy's Becomes First Indian Pharma to be Listed on Dow Jones Index

Dr Reddy's is the first Indian pharmaceutical company to feature in  Standard & Poor's Dow Jones Sustainability World Index (DJSI World)  2023,  the pharmaceutical company said.  They have received international awards for our commitment and progress in sustainability and environmental, social and governance (ESG). 

Since its debut in the DJSI World, the company has maintained the Dow Jones Composite Index for Emerging Markets (DJSI EM) for eight consecutive years, based on the efforts of Dr Reddy in the Standard and Poor Global Corporate Sustainability category. Evaluation (S&P Global CSA) and other selection criteria.

Separately, Dr. Reddy's has been awarded Gold Medal status by EcoVadis, the global sustainability ratings agency, for its score of 70 out of 100 in its scorecard for 2023.

G V Prasad, Co-Chairman & Managing Director Dr. Reddy's, said: As a company with over two decades of experience in sustainability, we see it as our responsibility to set the bar high. Going beyond the environment, we have set ourselves ambitious and measurable goals for patients, employees and governance.

In addition to the global recognitions, Dr. Reddy's recently became the first Indian pharma company to join the World Economic Forum's (WEF) 1t.org community and pledged towards an integrated plantation initiative covering 2,900 hectares by 2028.